News | Proton Therapy | November 20, 2015

Mevion to Install Three-Room Proton Therapy System in Los Angeles

Installation will be done in phases, with first room opening for treatments in late 2017

Mevion S250mx, Los Angeles Proton Center, three-room proton therapy system

Image courtesy of Mevion Medical Systems

November 20, 2015 – Mevion Medical Systems is announcing the Los Angeles Proton Center is building a three-room Mevion S250mx proton therapy system. The system will include Mevion’s Hyperscan pencil beam scanning technology and will be installed near Los Angeles, in the city of Montebello, on the campus of Beverly Hospital. The installation will take place in phases, with the first of the three rooms treating cancer patients in late 2017.

“The Mevion S250mx was the optimal solution for our facility because it allows for a flexible, phased installation,” said Charles Liu, president of the Los Angeles Proton Center. “Just as importantly, we continue to be impressed with the proven results of all of Mevion’s clinically operational systems, including Mevion’s industry-leading ramp-up time, high patient throughput, and low staffing and maintenance requirements. The decision to select Mevion and its product solutions will allow us to consistently provide high-quality proton therapy to a large number of patients.”

The Mevion S250mx is the fully scalable version of Mevion’s proton therapy technology and is available in two-, three- or four-room configurations. Each room is fully independent, with its own proton accelerator, providing inherent redundancy and 100 percent facility uptime 365 days per year. 

The Los Angeles Proton Center is an independent proton center that will collaborate with renowned cancer specialists to treat adult and pediatric cancer patients from the Greater Los Angeles area. The center will also serve international patients who are seeking cancer care on the West Coast of the United States.

Similar Mevion systems have ramped up to full capacity in as little as three months and achieved an annualized rate of 350 patients per room, per year. That is more than 25 percent better than the average U.S. proton therapy center. 

The Los Angeles system is the third system purchase announced by Mevion in the past six weeks. In October, Mevion announced the installation of a Mevion S250 to Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, and a Mevion S250i with Hyperscan to the Ackerman Cancer Center in Jacksonville, Florida.

Hyperscan has not been cleared by the U.S. Food and Drug Administration for clinical use.

For more information: www.mevion.com

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.